Biocytogen Partners with Moonlight Bio to Develop Advanced Cell Therapies for Difficult-to-Treat Cancers
核心洞察
Biocytogen (搜索) Pharmaceuticals announced a strategic collaboration with Seattle-based Moonlight Bio (搜索) to develop cutting-edge cell therapies targeting challenging and difficult-to-treat cancers.
The partnership leverages Biocytogen (搜索)'s proprietary off-the-shelf fully human antibody library, which contains over 1,000,000 antibody sequences against more than 1,000 targets.
Under the agreement, Biocytogen (搜索) will provide antibody binders against therapeutic targets while Moonlight Bio (搜索) oversees preclinical development of enhanced cell therapies.
Biocytogen (搜索) Pharmaceuticals (Beijing) Co., Ltd. announced a strategic collaboration with Moonlight Bio (搜索), Inc., a Seattle-based biotechnology company, to develop advanced cell therapies targeting some of the most challenging and difficult-to-treat cancers. The partnership combines Biocytogen's proprietary antibody discovery platforms with Moonlight Bio's enhanced cell therapy technologies.
Partnership Structure and Technology Integration
Under the terms of the agreement, Biocytogen (搜索) will provide its off-the-shelf antibody binders against therapeutic targets, while Moonlight Bio (搜索) will oversee the preclinical development of cell therapies. The collaboration leverages Biocytogen's RenSuper™ Biologics platform, which offers an off-the-shelf library containing over 1,000,000 fully human antibody sequences against more than 1,000 targets for worldwide collaboration.
Dr. Yuelei Shen, President and CEO of Biocytogen (搜索), emphasized the strategic importance of the partnership: "We are thrilled to partner with Moonlight Bio (搜索), a pioneering leader in advanced cell therapies. This strategic collaboration leverages our proprietary off-the-shelf fully human antibody library to accelerate the development of cutting-edge cell therapies for difficult-to-treat cancers."
Addressing Treatment Resistance in Solid Tumors
The collaboration specifically targets the challenge of treatment resistance in solid tumors, where current therapies often fail to generate deep and durable responses. Moonlight Bio (搜索)'s core technologies are designed to enhance cell therapy potency, addressing what the company describes as "the disappointing reality that therapies for solid tumors are simply not potent enough to generate the deep and durable responses that patients urgently need."
Dr. Shen noted that the partnership demonstrates "the versatility and broad applicability of Biocytogen (搜索)'s antibody discovery platforms beyond traditional drug modalities. By combining our expertise, we are poised to accelerate the development of transformative cell therapies that could overcome resistance and offer new hope to patients battling the toughest cancers."
Biocytogen's Platform Technology
Biocytogen (搜索) has established a dual-engine platform combining a fully human antibody library with an extensive target-humanized mouse model portfolio. The company has independently developed proprietary RenMice® platforms, including RenMab®/RenLite®/RenNano®/RenTCR™/RenTCR mimic™, for fully human monoclonal/bispecific/multispecific antibody discovery, bispecific antibody-drug conjugate discovery, hu-VHH discovery, and TCR mimic antibody discovery.
As of December 31, 2025, more than 350 agreements for therapeutic antibodies and clinical assets—spanning co-development, out-licensing, and transfers—have been established globally, including landmark partnerships with leading multinational pharmaceutical companies. The company also provides thousands of off-the-shelf animal and cell models under its BioMice™ sub-brand, along with preclinical pharmacology and gene-editing services.
Company Backgrounds
Biocytogen (搜索), listed on both the Shanghai Stock Exchange (SSE: 688796) and Hong Kong Exchange (HKEX: 02315), is a global biotechnology company founded on gene editing technology. The company is headquartered in Beijing with branches in China (Haimen, Jiangsu, Shanghai), the USA (Boston, San Francisco, San Diego), and Germany (Heidelberg).
Moonlight Bio (搜索) is a preclinical-stage biotechnology company based in Seattle, Washington, focused on developing potency-enhanced cell therapies for cancer patients. The company's technologies are specifically designed to address the limitations of current solid tumor therapies and provide enhanced therapeutic responses for patients with challenging cancers.